IRLAB A
14.65
SEK
TODAY
1.74 %
TODAY SEK
0.25 SEK
12:04:31
2025-02-21
YEAR LOW
8.72 SEK
YEAR HIGH
16.5 SEK
ATH:
108.09 SEK
MCAP:
765 MSEK

CEO COMMENTS

Kristina Torfgård comments Q3 report 2024

The important progress we made during the quarter, especially on our three most advanced projects mesdopetam, pirepemat and IRL757, has further strengthened our position, where the success of our projects bringing us closer to new and better treatments for people with Parkinson’s disease.”

LATEST REPORTS

LATEST PRESS RELEASE
FEBRUARY 20, 2025

IRLAB receives positive feedback from EMA confirming alignment with FDA on Phase III program for Mesdopetam

Gothenburg, Sweden, 20 February, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB a company discovering and developing novel treatments for Parkinson’s disease, today announces that the European Medicines Agency (EMA) has provided positive feedback on the company’s proposed design for the Phase III program of mesdopetam. Based on EMA’s guidance, IRLAB can now proceed with preparations for the registration studies of the drug candidate, which has demonstrated efficacy in a phase Ib and in two Phase II studies against levodopa-induced dyskinesia in patients with Parkinson’s disease.

Read More >
LATEST PRESENTATION
OCTOBER 25, 2024

Presentation at Redeye’s Theme Event Neurology

Presentation by Kristina Torfgård, CEO, at “Theme Event Neurology”, an event hosted by Redeye, held on October 23, 2024.

Read More >

FINANCIAL CALENDAR

NEXT

July 10, 2024

Interim Report January – June 2024